Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of Flonoltinib maleate tablets in patients with polycythemia vera
ChiCTR2500111413Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flonoltinib in polycythemia vera (PV) (6 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of subjects achieving hematocrit (HCT) control at week 28. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
flonoltinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ChiCTR2500111413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111413.